ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT.

S. Florman,1 A. Durrbach,2 V. Duro Garcia,3 K. Calderon,4 U. Meier-Kriesche,4 M. Polinsky,4 H. Zhao,4 J. Medina Pestana.5

1Mount Sinai Med Ctr, New York
2Univ Hôpital of Bicêtre, Le Kremlin-Bicêtre, France
3Hosp Dom Vicente Scherer, Porto Alegre, Brazil
4BMS, Lawrenceville
5Hosp do Rim, Sao Paulo, Brazil.

Meeting: 2016 American Transplant Congress

Abstract number: D134

Keywords: African-American, Cadaveric organs, Kidney transplantation

Session Information

Session Name: Poster Session D: Kidney Immunosuppression: Novel Agents

Session Type: Poster Session

Date: Tuesday, June 14, 2016

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Studies consistently show worse outcomes for black vs non-black kidney transplant recipients. At 7 yrs post-transplant in BENEFIT-EXT (NCT00114777), bela was associated with similar graft survival and improved renal function vs CsA. We examined outcomes by race in BENEFIT-EXT.

Recipients of extended criteria donor kidneys were randomized to bela more intense (MI), bela less intense (LI), or CsA immunosuppression. All randomized, transplanted pts were analyzed through 7 yrs. Time to death or graft loss was compared between regimens with Cox regression. Race and treatment effect were assessed. The interaction of treatment and race was also considered. GFR was estimated from months 1–84 using a repeated measures model.

Of 543 randomized pts, 71 were black and 472 were non-black. See figure for hazard ratios for the time to death or graft loss. Serious AE rates in black vs non-black pts were similar across regimens. In black and non-black pts, estimated mean GFR increased over 7 yrs for both bela regimens but declined for CsA. In black pts, GFR slopes diverged over time between bela MI and CsA (P=.024), but not bela LI and CsA (P=.10). In non-black pts, GFR slopes diverged between bela and CsA over time; the interaction of the treatment vs time effect deriving from the model favored each bela regimen vs CsA (P≤.0012).

In this post-hoc analysis, bela-treated black and non-black pts exhibited similar outcomes. Although estimated mean GFR was higher in black pts treated with bela vs CsA, interpretation is limited by the small number of black pts.

 

Black

(n=71)

   

Non-black

(n=472)

   
Bela MI Bela LI CsA Bela MI Bela LI CsA
Pts evaluable for death or graft loss at month 84, n/N 14/25 16/24 15/22 114/159 122/151 93/162
Acute rejection by month 84, n/N 5/25 4/24 6/22 30/159 30/151 23/162
Serious AE, % 80 83 91 88 90 83
Estimated mean GFR at month 84, mL/min/1.73 m2 65.1 55.9 31.0 52.0 53.8 36.3

CITATION INFORMATION: Florman S, Durrbach A, Duro Garcia V, Calderon K, Meier-Kriesche U, Polinsky M, Zhao H, Medina Pestana J. Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Florman S, Durrbach A, Garcia VDuro, Calderon K, Meier-Kriesche U, Polinsky M, Zhao H, Pestana JMedina. Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-in-black-vs-non-black-patients-administered-belatacept-bela-or-cyclosporine-csa-in-benefit-ext/. Accessed June 2, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences